Aurelio Castrellon

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Hope S. Rugo, Richard S. Finn, Véronique Dièras et al. · Breast Cancer Research and Treatment · 2019 · 442 citations · Full text

Medicine, Oncology, Pharmacology +17

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

CH Barcenas, Sara A. Hurvitz, Jack A. Di Palma et al. · Annals of Oncology · 2020 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Christopher Lobo, Gilberto Lopes, Odalys Baez et al. · Breast Cancer Research and Treatment · 2010 · 89 citations

Medicine, Oncology, Pharmacology +17

Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation

Julio A. Chirinos, Aurelio Castrellon, Juan P. Zambrano et al. · Heart Rhythm · 2005 · 62 citations

Medicine, Cardiology, Pharmacology +11

Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

Hope S. Rugo, Richard S. Finn, Karen A. Gelmon et al. · Clinical Breast Cancer · 2019 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17